title: Reply to A. Oguz et al.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD ciara.o'sullivan@nih.gov.
authors.forename: Ciara C
authors.initials: CC
authors.lastname: O'Sullivan
authors.affiliation: Frontier Science, Inverness-shire, Scotland.
authors.forename: Eileen
authors.initials: E
authors.lastname: Holmes
authors.affiliation: Frontier Science, Inverness-shire, Scotland.
authors.forename: Christine
authors.initials: C
authors.lastname: Campbell
authors.affiliation: Frontier Science, Inverness-shire, Scotland.
authors.forename: Ian
authors.initials: I
authors.lastname: Bradbury
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Jo Anne
authors.initials: JA
authors.lastname: Zujewski
authors.affiliation: Harvard Medical School, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases